Levofolino Rugštis Medac (Levoleucovorin Disodium)

Levoleucovorin Disodium supplies a reduced folate that bypasses the inhibition of dihydrofolate reductase caused by antifolate drugs. By entering the folate cycle directly, it restores DNA synthesis in healthy cells, counteracting the cytotoxic impact of agents such as methotrexate while leaving tumor cells largely unaffected.

The dose of Levofolino Rugštis Medac is individualized by the prescribing oncologist or pharmacist based on the specific chemotherapy regimen, patient renal and hepatic function, and the timing relative to methotrexate administration. No standard dosing can be provided without a medical prescription.

The safety of levoleucovorin disodium in pregnancy and lactation has not been definitively established. It should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Levofolino Rugštis Medac (levoleucovorin disodium) is a sodium salt form of leucovorin that offers higher solubility and stability for intravenous use compared with calcium leucovorin. Clinical efficacy in methotrexate rescue is comparable, while the formulation may allow more precise dosing and easier preparation in a hospital pharmacy.

Levofolino Rugštis Medac should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

The medication is supplied as a sterile powder for reconstitution and is administered intravenously, typically as an infusion over a defined period after high‑dose methotrexate. Administration details, including infusion rate and timing, are determined by the treating physician.

Serious adverse events include acute renal failure, severe hypersensitivity or anaphylaxis, marked hepatic dysfunction, and bone‑marrow suppression leading to pancytopenia. Prompt recognition and medical intervention are essential if any of these reactions occur.

Patients with known hypersensitivity to levoleucovorin or any component of the formulation should avoid its use. Caution is also advised in individuals with severe renal or hepatic impairment, and the drug should not be given without proper medical supervision in pregnant or breastfeeding women unless clearly indicated.